• Wondering whether Xylem's share price still reflects fair value, or if the recent moves have opened up a mispricing worth your attention.
• The stock recently closed at US$110.87, with a small 0.5% gain over the last 7 days, a 2.5% decline over the past month, and a year to date fall of 19.1% that leaves the 1-year return down 12.6% and the 3-year and 5-year returns at 3.8% and 0.3% respectively.
• Recent news coverage has focused on Xylem's role in the broader capital goods sector and ongoing interest in companies tied to water infrastructure and related solutions. This context helps explain why the share price has seen short-term swings as investors reassess both risk and potential reward.
• On Simply Wall St's valuation checks, Xylem currently scores a 5 out of 6. This sets up a closer look at traditional tools such as P/E multiples and discounted cash flow, before turning to a different way of thinking about valuation at the end of this article.

Approach 1: Xylem Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required rate of return. It focuses on the cash the company is expected to generate for shareholders rather than just current earnings or book value.

For Xylem, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $960.7 million. Analyst projections and Simply Wall St extrapolations point to Free Cash Flow reaching around $2.2 billion by 2035, with interim points such as $970.1 million in 2026 and $1.6 billion in 2029. All of these forecast cash flows are converted to today’s terms using a discount rate to reflect risk and the time value of money.

Using these inputs, the DCF output suggests an estimated intrinsic value of about $128.50 per share, compared with the recent share price of $110.87. This comparison implies the stock trades at about a 13.7% discount to this intrinsic value on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Xylem is undervalued by 13.7%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Xylem Price vs Earnings

For a profitable company like Xylem, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of current earnings. It links directly to what the business is earning today, which many investors treat as a key anchor for assessing valuation.

What counts as a “normal” P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually calls for a lower one.

Xylem currently trades on a P/E of 26.86x. That is close to both the Machinery industry average of 27.13x and the broader peer group average of 39.96x. Simply Wall St’s Fair Ratio for Xylem is 27.24x, which is a proprietary estimate of what the P/E could be given factors such as earnings growth, profit margins, industry, market cap and risk profile. Because it adjusts for these company specific drivers, the Fair Ratio can be more tailored than a simple comparison with industry or peer averages. The current P/E of 26.86x sits very close to the Fair Ratio of 27.24x, suggesting the valuation is about in line with these fundamentals.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Xylem Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives put your view of Xylem’s story into a simple framework that links what you believe about its future revenue, earnings and margins to a forecast and a Fair Value that you can compare with today’s price.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors. You can set assumptions, see the resulting Fair Value next to the live share price, and update your view as fresh information such as earnings releases or news arrives.

For Xylem, one investor might build a Narrative closer to the bullish Fair Value of about US$186.00 that leans into recurring digital revenues and margin expansion. Another might anchor on the more cautious Fair Value near US$123.56 that focuses on competition, budget constraints and execution risk. Comparing your own Fair Value range with the current share price can help you decide whether the stock appears appealing, fairly priced, or less attractive based on your assumptions.

Do you think there's more to the story for Xylem? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.